Cargando…
An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro
BACKGROUND: Phase-change ultrasound contrast agents (PCCAs) offer a solution to the inherent limitations associated with using microbubbles for sonoporation; they are characterized by prolonged circulation lifetimes, and their nanometer-scale sizes may allow for passive accumulation in solid tumors....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260003/ https://www.ncbi.nlm.nih.gov/pubmed/28127427 http://dx.doi.org/10.1186/s40349-017-0085-z |
_version_ | 1782499321737904128 |
---|---|
author | Fix, Samantha M. Novell, Anthony Yun, Yeoheung Dayton, Paul A. Arena, Christopher B. |
author_facet | Fix, Samantha M. Novell, Anthony Yun, Yeoheung Dayton, Paul A. Arena, Christopher B. |
author_sort | Fix, Samantha M. |
collection | PubMed |
description | BACKGROUND: Phase-change ultrasound contrast agents (PCCAs) offer a solution to the inherent limitations associated with using microbubbles for sonoporation; they are characterized by prolonged circulation lifetimes, and their nanometer-scale sizes may allow for passive accumulation in solid tumors. As a first step towards the goal of extravascular cell permeabilization, we aim to characterize the sonoporation potential of a low-boiling point formulation of PCCAs in vitro. METHODS: Parameters to induce acoustic droplet vaporization and subsequent microbubble cavitation were optimized in vitro using high-speed optical microscopy. Sonoporation of pancreatic cancer cells in suspension was then characterized at a range of pressures (125–600 kPa) and pulse lengths (5–50 cycles) using propidium iodide as an indicator molecule. RESULTS: We achieved sonoporation efficiencies ranging from 8 ± 1% to 36 ± 4% (percent of viable cells), as evidenced by flow cytometry. Increasing sonoporation efficiency trended with increasing pulse length and peak negative pressure. CONCLUSIONS: We conclude that PCCAs can be used to induce the sonoporation of cells in vitro, and our results warrant further investigation into the use of PCCAs as extravascular sonoporation agents in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40349-017-0085-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5260003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52600032017-01-26 An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro Fix, Samantha M. Novell, Anthony Yun, Yeoheung Dayton, Paul A. Arena, Christopher B. J Ther Ultrasound Research BACKGROUND: Phase-change ultrasound contrast agents (PCCAs) offer a solution to the inherent limitations associated with using microbubbles for sonoporation; they are characterized by prolonged circulation lifetimes, and their nanometer-scale sizes may allow for passive accumulation in solid tumors. As a first step towards the goal of extravascular cell permeabilization, we aim to characterize the sonoporation potential of a low-boiling point formulation of PCCAs in vitro. METHODS: Parameters to induce acoustic droplet vaporization and subsequent microbubble cavitation were optimized in vitro using high-speed optical microscopy. Sonoporation of pancreatic cancer cells in suspension was then characterized at a range of pressures (125–600 kPa) and pulse lengths (5–50 cycles) using propidium iodide as an indicator molecule. RESULTS: We achieved sonoporation efficiencies ranging from 8 ± 1% to 36 ± 4% (percent of viable cells), as evidenced by flow cytometry. Increasing sonoporation efficiency trended with increasing pulse length and peak negative pressure. CONCLUSIONS: We conclude that PCCAs can be used to induce the sonoporation of cells in vitro, and our results warrant further investigation into the use of PCCAs as extravascular sonoporation agents in vivo. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40349-017-0085-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-24 /pmc/articles/PMC5260003/ /pubmed/28127427 http://dx.doi.org/10.1186/s40349-017-0085-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Fix, Samantha M. Novell, Anthony Yun, Yeoheung Dayton, Paul A. Arena, Christopher B. An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro |
title | An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro |
title_full | An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro |
title_fullStr | An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro |
title_full_unstemmed | An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro |
title_short | An evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro |
title_sort | evaluation of the sonoporation potential of low-boiling point phase-change ultrasound contrast agents in vitro |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5260003/ https://www.ncbi.nlm.nih.gov/pubmed/28127427 http://dx.doi.org/10.1186/s40349-017-0085-z |
work_keys_str_mv | AT fixsamantham anevaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro AT novellanthony anevaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro AT yunyeoheung anevaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro AT daytonpaula anevaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro AT arenachristopherb anevaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro AT fixsamantham evaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro AT novellanthony evaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro AT yunyeoheung evaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro AT daytonpaula evaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro AT arenachristopherb evaluationofthesonoporationpotentialoflowboilingpointphasechangeultrasoundcontrastagentsinvitro |